build confidence in a generic drug program when customer satisfaction is a challenge. And I think I will really need your help as we move in that direction, how to do that. Clearly, we have a lot of work ahead of us in trying to sort things out and clearly define the issues and explain the processes that we adopt and the science that we have to our customers, not only the patients but the physicians and the pharmacists out there.
I think on day one, I think the key issue that is in my mind is the topical products, whether they are topical products for skin. I think many of the issues are also customer issues and customer perceptions on quality of generic drugs. So we struggle with pharmaceutical equivalence there and now we struggle with bioequivalence.
With that, I think again I thank all of you for your patience and your advice and we'll take this seriously and at the same time, all the comments we have received from the public, we'll take that into consideration and work towards the next advisory committee.
DR. KIBBE: I'd just like to thank Ajaz, Helen, and the rest of the FDA staff for doing the best